Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ApoE determines the metabolic fate of apoC-III

ABSTRACT: ApoE determines the metabolic fate of apoC-III

PROVIDER: PRJNA543116 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9062590.fastq.gz	Fastqsanger.gz
	SRR9062591.fastq.gz	Fastqsanger.gz
	SRR9062592.fastq.gz	Fastqsanger.gz
	SRR9062593.fastq.gz	Fastqsanger.gz
	SRR9062594.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

ApoE determines the metabolic fate of apoC-III

Project description:Hypertriglyceridemia results from accumulation of triglyceride (TG)-rich lipoproteins (TRLs) in the circulation and is associated with increased cardiovascular disease risk. ApoC-III is an apolipoprotein on TRLs and a prominent negative regulator of TG catabolism. We recently established that in vivo apoC-III predominantly inhibits LDLR and LRP1 mediated hepatic TRL clearance and that apoC-III enriched TRLs are preferentially cleared by syndecan-1 (SDC1). In this study, we determined the impact of apoE, a common ligand for all three receptors, on apoC-III metabolism using apoC-III antisense oligonucleotide (ASO) treatment in mice lacking apoE and functional SDC1 (Apoe(-/-) Ndst1(f/f) Alb-Cre+). ApoC-III ASO treatment significantly reduced plasma TG levels in Apoe(-/-) Ndst1(f/f) Alb-Cre+ mice without reducing hepatic VLDL production or improving hepatic TRL clearance. Further analysis revealed that apoC-III ASO treatment lowered plasma TGs in Apoe(-/-) Ndst1(f/f) Alb-Cre+ mice, which was associated with increased LPL activity in white adipose tissue (WAT) in the fed state. Finally, clinical data confirm that ASO-mediated lowering of apoC-III via volanesorsen can reduce plasma TG levels independent of the apoE isoform genotype. Our data indicate that apoE determines the metabolic impact of apoC-III as we establish that apoE is essential to mediate inhibition of TRL clearance by apoC-III and that in the absence of functional apoE apoC-III inhibits tissue LPL activity.

2019-05-24 | GSE131284 | GEO

Protein translation rate determines neocortical neuron fate

Project description:Protein translation rate determines neocortical neuron fate

| PRJNA723552 | ENA

Transcriptional Reprogramming during Floral Fate Acquisition III

Project description:Transcriptional Reprogramming during Floral Fate Acquisition III

| PRJNA844349 | ENA

Subcellular Localization Shapes the Fate of RNA Polymerase III

Project description:RNA Pol III plays a vital role in transcription and as a viral-DNA sensor, but how it is assembled and distributed within cells remain poorly understood. Here, we show that Pol III is assembled with chaperones in the cytoplasm and forms transcription-dependent protein clusters upon transport into the nucleus. The largest subunit (RPC1) depletion through an auxin-inducible degron leads to rapid degradation and disassembly of Pol III complex in the nucleus and cytoplasm, respectively. This generates a pool of partially assembled Pol III intermediates, which can be rapidly mobilized into the nucleus upon the restoration of RPC1. Our study highlights the critical role of subcellular localization in determining Pol III's fate and provide insight into the dynamic regulation of nuclear Pol III levels and the origin of cytoplasmic Pol III complexes involved in mediating viral immunity.

2022-11-06 | PXD037971 |

Subcellular Localization Shapes the Fate of RNA Polymerase III-2

2023-05-29 | PXD042522 |

Metabolic state determines drug response in liver cancer

Project description:Metabolic state determines drug response in liver cancer

| PRJNA507425 | ENA

TCF1 dosage determines cell fate during T cell development.

Project description:TCF1 dosage determines cell fate during T cell development.

| PRJNA1152920 | ENA

TCF1 dosage determines cell fate during T cell development

Project description:TCF1 dosage determines cell fate during T cell development

| PRJNA1124978 | ENA